Schroder Investment Management Group Increases Stock Holdings in Intellia Therapeutics, Inc. $NTLA

Key Points

• Schroder Investment Management boosted its stake in Intellia by 1,593.4% in Q2, buying 382,425 shares to hold 406,425 shares (about 0.39% of the company) valued at $3.81 million.
• Wall Street sentiment is mixed: the consensus rating is "Hold" with an average price target of $18.43 after several firms cut ratings or lowered targets (11 Buy, 10 Hold, 3 Sell).
• NTLA trades around $9.61 with a $1.11B market cap; the company beat Q results with ($0.92) EPS and revenue up 51.6% year-over-year but remains unprofitable.

Schroder Investment Management Group increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1,593.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 406,425 shares of the company's stock after purchasing an additional 382,425 shares during the quarter. Schroder Investment Management Group owned 0.39% of Intellia Therapeutics worth $3,812,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Intellia Therapeutics by 5.5% during the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock valued at $76,447,000 after acquiring an additional 561,978 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 5.1% during the 2nd quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company's stock worth $24,449,000 after purchasing an additional 126,049 shares during the period. JPMorgan Chase & Co. grew its holdings in Intellia Therapeutics by 73.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company's stock valued at $8,822,000 after purchasing an additional 396,858 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its position in Intellia Therapeutics by 104.7% in the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company's stock worth $5,988,000 after purchasing an additional 326,460 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company's stock worth $3,709,000 after purchasing an additional 38,521 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of analyst reports. William Blair cut Intellia Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Monday, October 27th. Bank of America dropped their price objective on Intellia Therapeutics from $36.00 to $30.00 and set a "buy" rating for the company in a report on Monday, October 27th. Chardan Capital reduced their target price on Intellia Therapeutics from $48.00 to $26.00 and set a "buy" rating on the stock in a research note on Friday, November 7th. Tudor Pickering set a $14.50 target price on Intellia Therapeutics in a research report on Tuesday, October 28th. Finally, Wall Street Zen lowered shares of Intellia Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, November 30th. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $18.43.

Intellia Therapeutics Trading Down 1.3%

Shares of NTLA stock opened at $9.61 on Friday. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $28.25. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -2.25 and a beta of 2.13. The stock has a fifty day simple moving average of $15.33 and a two-hundred day simple moving average of $12.55.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.10. The firm had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business's revenue for the quarter was up 51.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.34) earnings per share. Research analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of the firm's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares of the company's stock, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.10% of the company's stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.